A brand new worldwide analysis programme will examine whether or not glucagon-like peptide-1 (GLP-1) receptor agonists ‒ extensively used to deal with diabetes and weight problems ‒ could possibly be repurposed to forestall the development of clonal haematopoiesis and its related illnesses.
The GLP-1RA Use to Attenuate Danger and Illness related to Clonal Hematopoiesis (GUARD-CH) programme, co-led by Philip Awadalla, Professor of Molecular Genetics at Oxford Inhabitants Well being and the College of Oxford’s Huge Knowledge Institute, and Professor Stephanie Xie at Princess Margaret Most cancers Centre, Toronto, has acquired £1.25 million in funding from Most cancers Analysis UK and the Canadian Most cancers Society.
Clonal haematopoiesis is a standard age-related situation by which blood-forming stem cells carrying acquired mutations develop extra quickly than different stem cells. It impacts as much as one-third of adults over 60 and is more and more detected in youthful individuals with metabolic illness.
Though it doesn’t itself represent most cancers, clonal haematopoiesis can considerably improve the chance of myelodysplastic syndromes and acute myeloid leukaemia (blood cancers). It could additionally promote systemic irritation, contributing to heart problems, stroke and different persistent circumstances. Professor Awadalla stated
“Inflammatory and metabolic stresses ‒ together with weight problems, diabetes, poor food plan and air air pollution ‒ could create circumstances that favour the enlargement of mutant blood stem cells.” — Prof. Philip Awadalla, professor of Molecular Genetics at Oxford Inhabitants Well being and the College of Oxford’s Huge Knowledge Institute.
The programme builds on compelling preliminary proof from the crew’s latest examine, “Human haematopoietic stem cells keep in mind inflammatory stress,” printed in Nature. The examine recognized a beforehand unrecognised subset of human blood stem cells that retains a sturdy molecular reminiscence of inflammatory publicity.
“The newly funded programme will check whether or not GLP-1 receptor agonists similar to semaglutide can disrupt this cycle by lowering irritation and eradicating the aggressive benefit of mutant cells. Our final aim is to ascertain whether or not an present and extensively prescribed class of medicines could possibly be used to forestall blood cancers and different illnesses in individuals with clonal haematopoiesis.” — Prof. Philip Awadalla.
This inflammatory reminiscence state was enriched in ageing, extreme an infection and clonal haematopoiesis, and its molecular signature could possibly be detected in mature circulating blood cells. In population-level analyses, a stronger inflammatory reminiscence signature was related to a better danger of clonal haematopoiesis or demise from varied causes. These findings present each a organic mechanism and a measurable molecular sign by which the preventive results of GLP-1 therapies can now be examined.
Oxford Inhabitants Well being will lead the brand new programme’s population-scale and computational elements, drawing on experience from throughout the division and the Huge Knowledge Institute in molecular epidemiology, genomics, multimodal information integration and worldwide cohort research.
The crew will even develop a sensible blood check that measures markers of illness to determine people most definitely to profit. This can be evaluated by the GUARD-CH potential examine in Canada and the UK, in partnership with Perspectum. The examine will comply with individuals with clonal haematopoiesis and metabolic illness for as much as 4 years.
Collectively, these research will generate the organic, inhabitants and medical proof wanted to design a future randomised most cancers prevention medical trial.
Reference: Zeng AGX, Nagree MS, Jakobsen NA, et al. Human haematopoietic stem cells keep in mind inflammatory stress. Nature. 2026;655(8122):458-467. doi: 10.1038/s41586-026-10522-7
This text has been republished from supplies linked above. Be aware: materials could have been edited for size and content material. For additional info, please contact the cited supply.
